Skip to content
← Back to this collection

PUBLICATIONS · 25049327

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2014 Sep 20
First author
Roberts KG

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Roberts KG
      type
      Author
    2. name
      Pei D
      type
      Author
    3. name
      Campana D
      type
      Author
    4. name
      Payne-Turner D
      type
      Author
    5. name
      Li Y
      type
      Author
    6. name
      Cheng C
      type
      Author
    7. name
      Sandlund JT
      type
      Author
    8. name
      Jeha S
      type
      Author
    9. name
      Easton J
      type
      Author
    10. name
      Becksfort J
      type
      Author
    11. name
      Zhang J
      type
      Author
    12. name
      Coustan-Smith E
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Roberts KG
      type
      Author
    2. name
      Pei D
      type
      Author
    3. name
      Campana D
      type
      Author
    4. name
      Payne-Turner D
      type
      Author
    5. name
      Li Y
      type
      Author
    6. name
      Cheng C
      type
      Author
    7. name
      Sandlund JT
      type
      Author
    8. name
      Jeha S
      type
      Author
    9. name
      Easton J
      type
      Author
    10. name
      Becksfort J
      type
      Author
    11. name
      Zhang J
      type
      Author
    12. name
      Coustan-Smith E
      type
      Author
    bibliography ids
    1. nci-bib-6babc189ab23d8c99f0a13ce
    book metadata
    content sha256
    65250474e03087dad63534f6cd8e68edd97a6d7d5ad4c819dc85c9eee2cceb59
    document type
    citation
    dois
    1. 10.1200/JCO.2014.55.4105
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:25049327
    immutable id
    pubmed:25049327@65250474e03087dad63534f6cd8e68edd97a6d7d5ad4c819dc85c9eee2cceb59
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    27
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    3012-20
    volume
    32
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      25049327
      provenance
      batch id
      69903be8ceab8801c81a
      provider
      NCBI PubMed ESummary
      record sha256
      903d57fda282683798a712b6600ef6aeaa7b7cda311b55c454642ec0938425e3
      response sha256
      1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
      retrieved at
      2026-09-09T23:47:05.208886+00:00
      publication date
      display
      2014 Sep 20
      precision
      day
      year
      2014
      publication types
      1. Journal Article
      2. Research Support, N.I.H., Extramural
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/25049327/
      title
      Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

      Preserved source evidence · Independent clinical review pending · Not medical advice